NCT07617337 2026-06-01AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerChugai PharmaceuticalPhase 1 Not yet recruiting102 enrolled
NCT06092086 2023-10-23Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCGuangdong Association of Clinical TrialsPhase 2 Recruiting126 enrolled